Cargando…

Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis

BACKGROUND: Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV...

Descripción completa

Detalles Bibliográficos
Autores principales: Riccio, Eleonora, Sabbatini, Massimo, Capuano, Ivana, Pellegrino, Angela Maria, Petruzzelli, Luigi Annicchiarico, Pisani, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035732/
https://www.ncbi.nlm.nih.gov/pubmed/32087684
http://dx.doi.org/10.1186/s12882-020-01716-w
_version_ 1783500115956203520
author Riccio, Eleonora
Sabbatini, Massimo
Capuano, Ivana
Pellegrino, Angela Maria
Petruzzelli, Luigi Annicchiarico
Pisani, Antonio
author_facet Riccio, Eleonora
Sabbatini, Massimo
Capuano, Ivana
Pellegrino, Angela Maria
Petruzzelli, Luigi Annicchiarico
Pisani, Antonio
author_sort Riccio, Eleonora
collection PubMed
description BACKGROUND: Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective. METHODS: Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al. Human and material resources utilization was recorded during each iron administration. According to study perspective, direct and indirect costs were considered. Costs for each resource unit were taken from official Italian sources. Probabilistic sensitivity analyses were carried out to test the robustness of the results. RESULTS: The base case analysis showed an average cost/cycle per patient of € 111 for oral iron and € 1302 for IV iron. Thus, the potential saving was equal to € 1191 per patient/cycle. The sensitivity analysis showed that the most sensitive driver is the time loss by patient and caregivers for the therapy and related-care, followed by the minutes of nursing care and the number of kilometres travelled to reach the referral centre. DISCUSSION: This study showed that oral Sucrosomial® iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent.
format Online
Article
Text
id pubmed-7035732
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-70357322020-03-02 Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis Riccio, Eleonora Sabbatini, Massimo Capuano, Ivana Pellegrino, Angela Maria Petruzzelli, Luigi Annicchiarico Pisani, Antonio BMC Nephrol Research Article BACKGROUND: Oral iron is recommended as first line treatment of anemia in non-dialysis chronic kidney disease (ND-CKD) patients. Sucrosomial® iron, a new generation oral iron with high absorption and bioavailability and a low incidence of side effects, has shown to be not inferior to intravenous (IV) iron in the replacement of iron deficiency anemia in patients with ND-CKD. Besides the clinical benefit, it is also important to determine the comparative total costs of oral versus IV iron administrations. The aim of this study was to perform a cost-minimization analysis of oral Sucrosomial iron, compared with IV iron gluconate from an Italian societal perspective. METHODS: Cost analysis was performed on the 99 patients with ND-CKD and iron-deficiency anemia of the randomized trial by Pisani et al. Human and material resources utilization was recorded during each iron administration. According to study perspective, direct and indirect costs were considered. Costs for each resource unit were taken from official Italian sources. Probabilistic sensitivity analyses were carried out to test the robustness of the results. RESULTS: The base case analysis showed an average cost/cycle per patient of € 111 for oral iron and € 1302 for IV iron. Thus, the potential saving was equal to € 1191 per patient/cycle. The sensitivity analysis showed that the most sensitive driver is the time loss by patient and caregivers for the therapy and related-care, followed by the minutes of nursing care and the number of kilometres travelled to reach the referral centre. DISCUSSION: This study showed that oral Sucrosomial® iron could offer specific advantages in terms of potential savings, and allowed identifying some implications for future research. Such advantages still persist with the new single dose IV iron formulation available in the market, although to a lesser extent. BioMed Central 2020-02-22 /pmc/articles/PMC7035732/ /pubmed/32087684 http://dx.doi.org/10.1186/s12882-020-01716-w Text en © The Author(s) 2020 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Riccio, Eleonora
Sabbatini, Massimo
Capuano, Ivana
Pellegrino, Angela Maria
Petruzzelli, Luigi Annicchiarico
Pisani, Antonio
Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
title Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
title_full Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
title_fullStr Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
title_full_unstemmed Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
title_short Oral Sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis
title_sort oral sucrosomial® iron versus intravenous iron for recovering iron deficiency anaemia in nd-ckd patients: a cost- minimization analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7035732/
https://www.ncbi.nlm.nih.gov/pubmed/32087684
http://dx.doi.org/10.1186/s12882-020-01716-w
work_keys_str_mv AT riccioeleonora oralsucrosomialironversusintravenousironforrecoveringirondeficiencyanaemiainndckdpatientsacostminimizationanalysis
AT sabbatinimassimo oralsucrosomialironversusintravenousironforrecoveringirondeficiencyanaemiainndckdpatientsacostminimizationanalysis
AT capuanoivana oralsucrosomialironversusintravenousironforrecoveringirondeficiencyanaemiainndckdpatientsacostminimizationanalysis
AT pellegrinoangelamaria oralsucrosomialironversusintravenousironforrecoveringirondeficiencyanaemiainndckdpatientsacostminimizationanalysis
AT petruzzelliluigiannicchiarico oralsucrosomialironversusintravenousironforrecoveringirondeficiencyanaemiainndckdpatientsacostminimizationanalysis
AT pisaniantonio oralsucrosomialironversusintravenousironforrecoveringirondeficiencyanaemiainndckdpatientsacostminimizationanalysis